12th Annual FDA Sentinel Public Workshop

April 20-21, 2020 | USA

The Sentinel Initiative, an active medical product surveillance system, was established in response to the Food and Drug Administration (FDA) Amendments Act of 2007 and has become one of the Agency’s premier evidence generation platforms. The 12th Annual Sentinel Initiative Public Workshop is being convened on April 20-21, 2020 by the Robert J. Margolis, MD, Center for Health Policy under a cooperative agreement with the FDA. The two-day workshop will be held at the Washington Plaza Hotel in Washington, DC and provides an opportunity to discuss recent achievements and engage with the broader community of patients, consumers, and scientific stakeholders.

Spotlight

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.


OTHER PAST CONFERENCES

1st EuroAfrica Conference Cairo

February 9-13, 2023 | USA

EuroAfrica organising committee is honoured to announce the first edition of EuroAfrica organised in collaboration with our colleagues from the Egyptian Society of Critical Care and Emergency Medicine (ESCCEM).

Pharma USA 2023

March 28-29, 2023 | USA

These are the qualities of a healthcare system that actively serves its purpose – yet instead, the US is hindered by mounting financial toxicity, unprecedented politicization of science and eroding public trust.

World Congress on Pharmacology and Drug Safety (WCPDS - 23)

March 29, 2023 | Malaysia

We are pleased to announce the upcoming World Congress on Pharmacology and Drug Safety (WCPDS - 23), taking place on 29th March 2023 in George Town, Malaysia.

Pharmacies' new roles in pharmaceutical care

February 8-11, 2023 | Denmark

Pharmacies' new roles in pharmaceutical care: bridging research and practice, the strong connection between research and practice will be demonstrated with talks about the development of pharmacy practice and how pharmacy practice keeps developing in supporting patients, improving the use of medicine, communicating with patients etc.

Spotlight

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.

resources